View Item 

Show simple item record

Epidermal growth factor receptor, p16, cyclin D1, and p53 staining patterns for inverted papilloma
dc.contributor.authorLin, Giant C.en_US
dc.contributor.authorScheel, Adamen_US
dc.contributor.authorAkkina, Sarahen_US
dc.contributor.authorChinn, Stevenen_US
dc.contributor.authorGraham, Martinen_US
dc.contributor.authorKomarck, Christineen_US
dc.contributor.authorWalline, Heatheren_US
dc.contributor.authorMcHugh, Jonathan B.en_US
dc.contributor.authorPrince, Mark E.en_US
dc.contributor.authorCarey, Thomas Een_US
dc.contributor.authorZacharek, Mark A.en_US
dc.date.accessioned2013-12-04T18:57:37Z
dc.date.available2015-01-05T13:54:43Zen_US
dc.date.issued2013-11en_US
dc.identifier.citationLin, Giant C.; Scheel, Adam; Akkina, Sarah; Chinn, Steven; Graham, Martin; Komarck, Christine; Walline, Heather; McHugh, Jonathan B.; Prince, Mark E.; Carey, Thomas E; Zacharek, Mark A. (2013). "Epidermal growth factor receptor, p16, cyclin D1, and p53 staining patterns for inverted papilloma." International Forum of Allergy & Rhinology 3(11): 885-889.en_US
dc.identifier.issn2042-6976en_US
dc.identifier.issn2042-6984en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/101829
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherThiemeen_US
dc.subject.otherP53en_US
dc.subject.otherCyclin D1en_US
dc.subject.otherEGFRen_US
dc.subject.otherSinonasal Carcinomaen_US
dc.subject.otherInverted Papillomaen_US
dc.subject.otherP16en_US
dc.titleEpidermal growth factor receptor, p16, cyclin D1, and p53 staining patterns for inverted papillomaen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelAllergy and Clinical Immunologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/101829/1/alr21215.pdf
dc.identifier.doi10.1002/alr.21215en_US
dc.identifier.sourceInternational Forum of Allergy & Rhinologyen_US
dc.identifier.citedreferenceLombardi D, Tomenzoli D, Butta L, et al. Limitations and complications of endoscopic surgery for treatment for sinonasal inverted papilloma: a reassessment after 212 cases. Head Neck. 2011; 33: 1154 – 1161.en_US
dc.identifier.citedreferenceSham CL, To KF, Chan PK, Lee DL, Tong MC, van Hasselt CA. Prevalence of human papillomavirus, Epstein‐Barr virus, p21, and p53 expression in sinonasal inverted papilloma, nasal polyp, and hypertrophied turbinate in Hong Kong patients. Head Neck. 2012; 34: 520 – 533.en_US
dc.identifier.citedreferenceFranzmann MB, Buchwald C, Jacobsen GK, Lindeberg H. Expression of p53 in normal nasal mucosa and in sinonasal papillomas with and without associated carcinoma and the relation to human papillomavirus (HPV). Cancer Lett. 1998; 128: 161 – 164.en_US
dc.identifier.citedreferencePensak ML. Controversies in Otolaryngology. New York: Thieme; 2001.en_US
dc.identifier.citedreferenceBarnes L. Schneiderian papillomas and nonsalivary glandular neoplasms of the head and neck. Mod Pathol. 2002; 15: 279 – 297.en_US
dc.identifier.citedreferenceSham CL, Lee DL, van Hasselt CA, Tong MC. A case‐control study of the risk factors associated with sinonasal inverted papilloma. Am J Rhinol Allergy. 2010; 24: e37 – e40.en_US
dc.identifier.citedreferenceLesperance MM, Esclamado RM. Squamous cell carcinoma arising in inverted papilloma. Laryngoscope. 1995; 105: 178 – 183.en_US
dc.identifier.citedreferenceLawson W, Ho BT, Shaari CM, Biller HF. Inverted papilloma: a report of 112 cases. Laryngoscope. 1995; 105 ( 3 Pt 1 ): 282 – 288.en_US
dc.identifier.citedreferenceMirza S, Bradley PJ, Acharya A, Stacey M, Jones NS. Sinonasal inverted papillomas: recurrence, and synchronous and metachronous malignancy. J Laryngol Otol. 2007; 121: 857 – 864.en_US
dc.identifier.citedreferencevon Buchwald C, Bradley PJ. Risks of malignancy in inverted papilloma of the nose and paranasal sinuses. Curr Opin Otolaryngol Head Neck Surg. 2007; 15: 95 – 98.en_US
dc.identifier.citedreferenceMendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003; 21: 2787 – 2799.en_US
dc.identifier.citedreferenceAng KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002; 62: 7350 – 7356.en_US
dc.identifier.citedreferenceRubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF‐alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998; 90: 824 – 832.en_US
dc.identifier.citedreferenceKlussmann JP, Gultekin E, Weissenborn SJ, et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol. 2003; 162: 747 – 753.en_US
dc.identifier.citedreferenceSinghi AD, Westra WH. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus‐associated head and neck cancer based on a prospective clinical experience. Cancer. 2010; 116: 2166 – 2173.en_US
dc.identifier.citedreferenceSham CL, Woo JK, van Hasselt CA, Tong MC. Treatment results of sinonasal inverted papilloma: an 18‐year study. Am J Rhinol Allergy. 2009; 23: 203 – 211.en_US
dc.identifier.citedreferenceCarta F, Verillaud B, Herman P. Role of endoscopic approach in the management of inverted papilloma. Curr Opin Otolaryngol Head Neck Surg. 2011; 19: 21 – 24.en_US
dc.identifier.citedreferenceLawson W, Schlecht NF, Brandwein‐Gensler M. The role of the human papillomavirus in the pathogenesis of Schneiderian inverted papillomas: an analytic overview of the evidence. Head Neck Pathol. 2008; 2: 49 – 59.en_US
dc.identifier.citedreferenceBeck JC, McClatchey KD, Lesperance MM, Esclamado RM, Carey TE, Bradford CR. Human papillomavirus types important in progression of inverted papilloma. Otolaryngol Head Neck Surg. 1995; 113: 558 – 563.en_US
dc.identifier.citedreferenceMirza N, Montone K, Sato Y, Kroger H, Kennedy DW. Identification of p53 and human papilloma virus in Schneiderian papillomas. Laryngoscope. 1998; 108 ( 4 Pt 1 ): 497 – 501.en_US
dc.identifier.citedreferenceHwang CS, Yang HS, Hong MK. Detection of human papillomavirus (HPV) in sinonasal inverted papillomas using polymerase chain reaction (PCR). Am J Rhinol. 1998; 12: 363 – 366.en_US
dc.identifier.citedreferenceSyrjanen K, Syrjanen S. Detection of human papillomavirus in sinonasal papillomas: systematic review and meta‐analysis. Laryngoscope. 2013; 123: 181 – 192.en_US
dc.identifier.citedreferenceIshiji T. Molecular mechanism of carcinogenesis by human papillomavirus‐16. J Dermatol. 2000; 27: 73 – 86.en_US
dc.identifier.citedreferencePim D, Collins M, Banks L. Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. Oncogene. 1992; 7: 27 – 32.en_US
dc.identifier.citedreferencePrince ME, Ubell ML, Castro J, Ogawa H, Ogawa T, Narayan A, et al. Tissue‐preserving approach to extracting DNA from paraffin‐embedded specimens using tissue microarray technology. Head Neck. 2007; 29: 465 – 471.en_US
dc.identifier.citedreferenceAllende DS, Hoschar A, Batra P, Hunt JL. Dysplasia and carcinomas arising in Schneiderian papillomas, 20 years experience [Abstract 1056]. Mod Pathol. 2008; 21 ( 1s ): 231A. http://www.nature.com/modpathol/journal/v21/n1s/pdf/3801037a.pdf. Accessed August 11, 2013.en_US
dc.identifier.citedreferenceShah AA, Evans MF, Adamson CS, Peng Z, Rajendran V, Cooper K. HPV DNA is associated with a subset of Schneiderian papillomas but does not correlate with p16(INK4a) immunoreactivity. Head Neck Pathol. 2010; 4: 106 – 112.en_US
dc.identifier.citedreferenceCairns P, Polascik TJ, Eby Y, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet. 1995; 11: 210 – 212.en_US
dc.identifier.citedreferencevan der Riet P, Nawroz H, Hruban RH, et al. Frequent loss of chromosome 9p21‐22 early in head and neck cancer progression. Cancer Res. 1994; 54: 1156 – 1158.en_US
dc.identifier.citedreferenceKumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl‐xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol. 2008; 26: 3128 – 3137.en_US
dc.identifier.citedreferenceWorden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol. 2008; 26: 3138 – 3146.en_US
dc.identifier.citedreferenceReimers N, Kasper HU, Weissenborn SJ, et al. Combined analysis of HPV‐DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer. 2007; 120: 1731 – 1738.en_US
dc.identifier.citedreferenceLewis JS Jr, Chernock RD, Ma XJ, et al. Partial p16 staining in oropharyngeal squamous cell carcinoma: extent and pattern correlate with human papillomavirus RNA status. Mod Pathol. 2012; 25: 1212 – 1220.en_US
dc.identifier.citedreferenceChao JC, Fang SY. Expression of epidermal growth factor receptor in the inverted papilloma and squamous cell carcinoma of nasal cavity. Eur Arch Otorhinolaryngol. 2008; 265: 917 – 922.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
alr21215.pdf
Size:
593.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.